Kaya, Hakan <br/><br/>
Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.  [electronic resource] 

 -  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation  2002 
 - 544-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1083-8791 
<br/><br/><label>Standard No.: </label>10.1053/bbmt.2002.v8.pm12434949  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bone Marrow Transplantation<br/>Drug Evaluation<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Remission Induction--methods<br/>Retrospective Studies<br/>Rituximab<br/>Salvage Therapy<br/>Transplantation, Autologous<br/>Treatment Outcome